Sio Gene Therapies, Inc (SIOX)

Etorro trading 970x250
Sio Gene Therapies, Inc (SIOX) Logo

About Sio Gene Therapies, Inc

Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company’s clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson’s disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York. Address: 130 West 42nd Street, New York, NY, United States, 10036

Sio Gene Therapies, Inc News and around…

Latest news about Sio Gene Therapies, Inc (SIOX) common stock and company :

We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
12 Nov, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
12 Nov, 2021 Yahoo! Finance

– Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF – Granted Fast Track Designation for both AXO-AAV-GM1 and AXO-AAV-GM2 for the treatment of GM1 gangliosidosis and Tay-Sachs/Sandhoff disease – Three AXO-Lenti-PD GMP campaigns successfully completed fill and finish, achieving target titers using suspension-based manufacturing process; on-track to complete c

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
11 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus MerckCommences ...

Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease
11 Nov, 2021 Yahoo! Finance

- Completed three successful GMP campaigns using suspension-based manufacturing process- All batches achieved target titers and have successfully completed fill and finish- Qualified Person (QP) certification of at least one batch of clinical trial material on-track for Q4 2021 - Obtained scientific advice from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. regarding continued clinical development- Expect to provide program update in Q1 2022 NEW YORK and DURHAM, N.C.,

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
01 Nov, 2021 Yahoo! Finance

- Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations- Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (F

55 Biggest Movers From Friday
25 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on ...

12 Health Care Stocks Moving In Friday's Intraday Session
22 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's ...

54 Biggest Movers From Yesterday
22 Oct, 2021 FinancialContent

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares climbed 356.8% to close at $45.50 on Thursday following an ...

Sio Gene Therapies Announces Reorganization of R&D Group
21 Oct, 2021 Yahoo! Finance

Two new executive positions created in connection with departure of R&D HeadNEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, announced today that Gavin Corcoran, M.D., Chief Research and Development Officer, will be leaving the company effective November 12, 2021, to pursue an opportunity with a private hea

Top Penny Stocks to Buy Now? 3 Under $4 to Watch
21 Oct, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Oct, 2021 FinancialContent

Gainers Sio Gene Therapies (NASDAQ:SIOX) stock moved upwards by 22.79% to $2.64 during Thursday's regular session. ...

38 Stocks Moving In Thursday's Mid-Day Session
21 Oct, 2021 FinancialContent

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 132.3% to $23.14 following an announcement the company will ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Oct, 2021 FinancialContent

Gainers Sio Gene Therapies (NASDAQ:SIOX) shares rose 13.95% to $2.45 during Thursday's pre-market session. The ...

The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
21 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends ...

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
21 Oct, 2021 Yahoo! Finance

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of Type I (early infantile-onset) and Type II (late inf

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
21 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're getting right into the swing of things today with a look at the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

23 Stocks Moving in Thursday's Pre-Market Session
21 Oct, 2021 FinancialContent

Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) rose 34.9% to $13.44 in pre-market trading after announcement of a proposed ...

Sio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action
21 Oct, 2021 FinancialContent

Sio Gene Therapies Inc(NASDAQ: SIOX) hasannounced interim datafrom its Phase 1/2 study of AXO-AAV-GM1, its ...

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
21 Oct, 2021 Yahoo! Finance

Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSW

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct, 2021 FinancialContent

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...

10 Top Penny Stocks To Watch This Week With Potential Biotech Catalysts
17 Oct, 2021 FinancialContent
Interesting SIOX Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Sio Gene Therapies Inc (SIOX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SIOX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

3 ‘Must Watch’ Penny Stocks For Your Watchlist Right Now
05 Oct, 2021 FinancialContent
UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
04 Oct, 2021 Yahoo! Finance

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK, and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new clinical and preclinical data in two oral presen

Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
04 Oct, 2021 Yahoo! Finance

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosisNEW YORK and DURHAM, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new clinical and preclinical data in two oral present

12 Health Care Stocks Moving In Friday's After-Market Session
24 Sep, 2021 FinancialContent

Gainers eFFECTOR Therapeutics (NASDAQ:EFTR) stock rose 4.43% to $17.91 during Friday's after-market session. The ...

Sio Gene Therapies to Participate in Upcoming Conferences
23 Sep, 2021 FinancialContent
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
22 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're halfway through the week and starting off Wednesday with a look at the biggest pre-market stock movers today. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

First Week of May 2022 Options Trading For Sio Gene Therapies (SIOX)
21 Sep, 2021 FinancialContent

Investors in Sio Gene Therapies Inc (SIOX) saw new options become available this week, for the May 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Quite a few insiders invested in Sio Gene Therapies Inc. (NASDAQ:SIOX) last year which is positive news for shareholders
13 Sep, 2021 Yahoo! Finance

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Sio Gene Therapies, Inc (SIOX) is a NASDAQ Common Stock listed in , ,

970x250